^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Chordoma
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chordoma: Useful in Certain Circumstances...Lapatinib for EGFR positive Chordomas.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Phase II study on lapatinib in advanced EGFR-positive chordoma

    Published date:
    04/04/2013
    Excerpt:
    Adults with progressive, advanced chordoma, expressing an EGFR, were eligible for the study…. All patients were evaluable for response. Six (33.3%) patients had PR and 7 (38.9%) SD, as their best Choi responses, corresponding to RECIST SD in all cases.
    DOI:
    10.1093/annonc/mdt117
    Trial ID:
    2009-014456-29